Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung

Lung Cancer

Volumn 61, Issue 1, 2008, Pages 54-60

  Song, Yoo Sung ^a   Lee, Won Woo ^a   Chung, Jin Haeng ^a   Park, So Yeon ^a   Kim, Yu Kyeong ^a   Kim, Sang Eun ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Carcinoid; FDG PET; Glucose transporter; Neuroendocrine lung tumor; Small cell lung carcinoma; SUV

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; PARAFFIN; PROTEIN ANTIBODY;

ADULT; AGED; ARTICLE; CARCINOID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG SMALL CELL CANCER; MALE; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HUMANS; LUNG NEOPLASMS; MALE; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 45649084820     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.11.012     Document Type: Article

References (32)

1. Travis W.D., Rush W., Flieder D.B., Falk R., Fleming M.V., Gal A.A., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22 (1998) 934-944
2. Takei H., Asamura H., Maeshima A., Suzuki K., Kondo H., Niki T., et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 124 (2002) 285-292
3. Chong S., Lee K.S., Chung M.J., Han J., Kwon O.J., and Kim T.S. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics 26 (2006) 41-57
4. Simon G.R., and Wagner H. Small cell lung cancer. Chest 123 (2003) 259S-271S
5. Gould M.K., Kuschner W.G., Rydzak C.E., Maclean C.C., Demas A.N., Shigemitsu H., et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 139 (2003) 879-892
6. Weber W.A., Petersen V., Schmidt B., Tyndale-Hines L., Link T., Peschel C., et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21 (2003) 2651-2657
7. Lee W.W., Chung J.H., Jang S.J., Eo J.S., Park S.Y., Sung S.W., et al. Consideration of serum glucose levels during malignant mediastinal lymph node detection in non-small-cell lung cancer by FDG-PET. J Surg Oncol 94 (2006) 607-613
8. Adams S., Baum R., Rink T., Schumm-Drager P.M., Usadel K.H., and Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25 (1998) 79-83
9. Wartski M., Alberini J.L., Leroy-Ladurie F., De Montpreville V., Nguyen C., Corone C., et al. Typical and atypical bronchopulmonary carcinoid tumors on FDG PET/CT imaging. Clin Nucl Med 29 (2004) 752-753
10. Erasmus J.J., McAdams H.P., Patz Jr. E.F., Coleman R.E., Ahuja V., and Goodman P.C. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 170 (1998) 1369-1373
11. Marom E.M., Sarvis S., Herndon II J.E., and Patz Jr. E.F. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology 223 (2002) 453-459
12. Chung J.K., Lee Y.J., Kim S.K., Jeong J.M., Lee D.S., and Lee M.C. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 25 (2004) 11-17
13. Chung J.H., Cho K.J., Lee S.S., Baek H.J., Park J.H., Cheon G.J., et al. Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging. J Nucl Med 45 (2004) 999-1003
14. Nguyen X.C., Lee W.W., Chung J.H., Park S.Y., Sung S.W., Kim Y.K., et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 62 (2007) 214-219
15. Wahl R. Principles of Cancer Imaging with Fluorodeoxyglucose. In: Wahl R. (Ed). Principles and Practice of Positron Emission Tomography (2002), Lippincott Williams and Wilkins, Philadelphia 100-110
16. www.intmed.mcw.edu/clincalc/body.html
17. Nakamoto Y., Zasadny K.R., Minn H., and Wahl R.L. Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-d-glucose. Mol Imaging Biol 4 (2002) 171-178
18. Bryant A.S., Cerfolio R.J., Klemm K.M., and Ojha B. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg 82 (2006) 417-422
19. Cerfolio R.J., and Bryant A.S. Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall-cell lung cancer. Ann Thorac Surg 83 (2007) 1826-1829
20. Chung J.H., Lee W.W., Park S.Y., Choe G., Sung S.W., Chung J.K., et al. FDG uptake and glucose transporter type 1 expression in lymph nodes of non-small cell lung cancer. Eur J Surg Oncol 32 (2006) 989-995
21. Mountain C.F., and Dresler C.M. Regional lymph node classification for lung cancer staging. Chest 111 (1997) 1718-1723
22. Higashi K., Ueda Y., Sakurai A., Wang X.M., Xu L., Murakami M., et al. Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med 27 (2000) 1778-1785
23. Mamede M., Higashi T., Kitaichi M., Ishizu K., Ishimori T., Nakamoto Y., et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 7 (2005) 369-379
24. Khandani A.H., Whitney K.D., Keller S.M., Isasi C.R., and Donald Blaufox M. Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer. Nucl Med Commun 28 (2007) 173-177
25. Younes M., Brown R.W., Stephenson M., Gondo M., and Cagle P.T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80 (1997) 1046-1051
26. Minami K., Saito Y., Imamura H., and Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 38 (2002) 51-57
27. Kruger S., Buck A.K., Blumstein N.M., Pauls S., Schelzig H., Kropf C., et al. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med 260 (2006) 545-550
28. Kamel E.M., Zwahlen D., Wyss M.T., Stumpe K.D., von Schulthess G.K., and Steinert H.C. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 44 (2003) 1911-1917
29. Kut V., Spies W., Spies S., Gooding W., and Argiris A. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol 30 (2007) 45-50
30. Chong S., Lee K.S., Kim B.T., Choi J.Y., Yi C.A., Chung M.J., et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol 188 (2007) 1223-1231
31. Daniels C.E., Lowe V.J., Aubry M.C., Allen M.S., and Jett J.R. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 131 (2007) 255-260
32. Buchmann I., Henze M., Engelbrecht S., Eisenhut M., Runz A., Schafer M., et al. Comparison of (68)Ga-DOTATOC PET and (111)In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34 (2007) 1617-1626